Acquired resistance to imatinib is due in 70–90% of GIST patients to the expansion of subpopulations harboring different KIT secondary mutations [8–10] that cluster in the ATP-binding pocket and the activation loop [5, 8–10]. This evidence concerns the gene KIT and gastrointestinal stromal tumor.